Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.

被引：0
|
作者：
Modi, Shanu
Elias, Anthony D.
LoRusso, Patricia
Samant, Meghna
Guardino, Ellie
Althaus, Betsy
Krop, Ian E.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Karmanos Canc Inst, Detroit, MI USA
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
528
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases
    Dong, Rongrong
    Ji, Jiali
    Liu, Hong
    He, Xuexin
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 : 20 - 26
  • [42] Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    ONCOLOGY REPORTS, 2013, 30 (03) : 1087 - 1093
  • [43] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
    Montemurro, Filippo
    Ellis, Paul
    Anton, Antonio
    Wuerstlein, Rachel
    Delaloge, Suzette
    Bonneterre, Jacques
    Quenel-Tueux, Nathalie
    Linn, Sabine C.
    Irahara, Natsumi
    Donica, Margarita
    Lindegger, Nicolas
    Barrios, Carlos H.
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 92 - 102
  • [45] Use of trastuzumab emtansine (T-DM1; K) after pertuzumab plus trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)
    Sanglier, T.
    Fabi, A.
    Flores, C.
    Flahavan, E.
    Lindegger, N.
    Montemurro, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab plus taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
    Ellis, Paul Anthony
    Barrios, Carlos H.
    Eiermann, Wolfgang
    Toi, Masakazu
    Im, Young-Hyuck
    Conte, Pier Franco
    Martin, Miguel
    Pienkowski, Tadeusz
    Pivot, Xavier B.
    Burris, Howard A.
    Strasak, Alexander
    Patre, Monika
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): Results from the phase I/randomized phase II TRAXHER2 study
    Cortes, Javier
    Dieras, Veronique
    Lorenzen, Sylvie
    Montemurro, Filippo
    Riera-Knorrenschild, Jorge
    Thuss-Patience, Peter
    Allegrini, Giacomo
    De laurentiis, Michele
    Lichinitser, Mikhail
    Lohrisch, Caroline
    Perez-Garcia, Jose
    Ricci, Francesco
    Sakaeva, Dina
    Serpanchy, Rosanne
    Sufliarsky, Jozef
    Vidal, Maria
    Irahara, Natsumi
    Wohlfarth, Christine
    Aout, Mounir
    Gelmon, Karen
    CANCER RESEARCH, 2018, 78 (13)
  • [48] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Peipei Liu
    Jiajun Fan
    Ziyu Wang
    Wenjing Zai
    Ping Song
    Yongping Li
    Dianwen Ju
    AMB Express, 10
  • [49] Trastuzumab Emtansine (T-DM1): No radiosensitizing effect in vitro on HER2-positive breast cancer cells (study in vitro)
    Mignot, Fabien
    Kirova, Youlia
    Verrelle, Pierre
    Teulade-Fichou, Marie-Paule
    Megnin-Chanet, Frederique
    CANCER RESEARCH, 2020, 80 (04)
  • [50] VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)
    Lindeman, Geoffrey J.
    Hamilton, Erika
    Krop, Ian
    Lim, Bora
    Modi, Shanu
    Saura, Cristina
    Desai, Rupal
    Danner, Bradford J.
    Fernando, Tharu M.
    Kong, Shengchun
    Legrand, Fatema A.
    Nasroulah, Federico
    CANCER RESEARCH, 2021, 81 (04)
12345